The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 142.50
Bid: 140.00
Ask: 145.00
Change: -10.00 (-6.56%)
Spread: 5.00 (3.571%)
Open: 152.50
High: 152.50
Low: 142.50
Prev. Close: 152.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of Minority Interest in Alkalon

29 May 2019 07:00

RNS Number : 3916A
Itaconix PLC
29 May 2019
 

29 May 2019

Itaconix plc ("Itaconix" or "the Company")

Sale of Minority Interest in Alkalon

Itaconix (AIM: ITX), a leading innovator in sustainable specialty polymers, announces the sale of its holdings in Alkalon A/S ("Alkalon"), a privately-held Danish nicotine gum company. The Company's holdings in Alkalon were purchased for cash by Helmich Invest ApS, Nolta ApS, Solco ApS, and Commerce Pharma Holding ApS, who are existing shareholders in Alkalon. The total cash consideration was c. DKK 2.0 million, equivalent to c. £242,000. The proceeds consisted of c. £194,000 for the Company's minority equity interest in Alkalon and c. £48,000 for the full principal and accrued interest of a shareholder loan.

Following impairments for fair value in 2016 and 2017, the book values for Alkalon in Itaconix's unaudited management accounts at 31 December 2018 were £46,000 for the minority equity interest in Alkalon and £30,000 for the shareholder loan and its accrued interest. 

Itaconix held 22.49% of Alkalon's ordinary shares. The Company recognised a profit of c.£5,000 for its share of Alkalon's profits in its unaudited management accounts for the year ended 31 December 2018 and a loss of c.£214,000 for the year ended 31 December 2017. 

As announced in 2016, Itaconix divested its nicotine gum business in return for an initial 15% equity holding in Alkalon. Subsequent shares from commercial milestones and minority participation in equity and debt funding increased the Company's stake to its holdings at the time of the sale.

Proceeds from the sale will be added to the Company's cash reserves and used for future working capital needs.

John R. Shaw, CEO of Itaconix, stated: "The sale of these last assets from Revolymer's legacy nicotine gum business marks the final step in transforming Itaconix into a technology innovator focused on emerging demands for sustainable specialty polymers."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

Ends

 

For further information please contact:

Itaconix plc

+1 603 775-4400

John R. Shaw / Michael Norris

N+1 Singer

+44 (0) 207 496 3000

Richard Lindley / James Moat (Corporate Finance)

Mia Gardner (Corporate Broking)

About Itaconix

Itaconix develops and produces bio-based specialty polymers that improve the safety, performance or sustainability of consumer and industrial products, with technology and market leadership positions in non-phosphate detergents, odour control, and hair styling.

www.itaconix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DISPGUPWAUPBPUR
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.